Faulty proteins may prove significant in identifying new treatments for ovarian cancer

	Tweet

A constellation of defective proteins suspected in causing a malfunction in the body’s ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a broad range of ovarian cancer patients, an Oregon Health & Science University Knight Cancer Institute study found.

These research results, published this week in PLoS ONE, have prompted additional exploration into whether the patient population included in clinical trials for drugs that target the enzyme poly ADP ribose polymerase (PARP) should be expanded. Several forms of cancer are more dependent on PARP for their growth than regular cells, which means that targeting these enzymes when they go haywire is a potentially effective way to treat ovarian cancer. Currently PARP inhibitors are being tested with patients who have two types of malfunctioning proteins, BRCA1 or BRCA2. But, the OHSU Knight Cancer Institute study of additional proteins, beyond BRCA proteins, suggests that they too are playing a role in driving ovarian cancer.

Tapping into the potential of PARP inhibitors could change the dynamics of ovarian cancer treatment. There has not been a substantial increase in treatment options for ovarian cancer in the past two decades, said Tanja Pejovic, M.D., Ph.D., gynecologic oncologist at the OHSU Knight Cancer Institute. Pejovic, who led the study of these additional defective proteins, added that the results provide evidence that further research into the role of multiple proteins is warranted.

Only about 10 to 15 percent of women with ovarian cancer have BRCA 1 or BRCA 2 mutations. Pejovic’s study of 186 patients with nonhereditary cancer found that 41 percent who had an early recurrence of the disease also had abnormal levels of the other proteins tracked. In contrast, only 19.5 percent of patients who hadn’t yet had a recurrence of the disease in three years had abnormal levels of these proteins.

“If we are able to identify the proteins that differentiate these patients at risk for early recurrence, this would open up a new direction in ovarian cancer treatment,” Pejovic said.

The study - which was supported by the Sherie Hildreth Ovarian Cancer (SHOC) Foundation - focused on proteins that are supposed to assist cells in repairing harmful breaks in DNA strands, a process called homologous recombination (HR). The malfunctioning of HR is not well understood in ovarian cancers where there is no family history of the disease. However, there is evidence that these proteins influence a patient’s ability to respond to drugs and their survival rates after treatment.

Ovarian cancer is the second most common gynecologic cancer and the most common cause of death among women with a gynecologic cancer. About 21,000 ovarian cancer cases are diagnosed annually and about 14,000 deaths occur each year from the disease.

The OHSU Knight Cancer Institute, which helped pioneer the field of personalized cancer medicine, is committed to research that identifies the specific mutations driving each individual patient’s cancer. Other researchers at the Knight Cancer Institute who contributed to the study are: Weiya Z. Wysham, M.D.; Hong Li, M.S., M.D.; Laura Hays, Ph.D.; Jay Wright; Nupur Pande, Ph.D.; and Maureen Hoatlin, Ph.D.

# # #
About the OHSU Knight Cancer Institute
With the latest treatments, technologies, hundreds of research studies and approximately 400 clinical trials, the OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle - an honor earned only by the nation’s top cancer centers. The honor is shared among the more than 650 doctors, nurses, scientists and staff who work together at the OHSU Knight Cancer Institute to reduce the impact of cancer.

About OHSU
Oregon Health & Science University is the state’s only health and research university and its only academic health center. As Portland’s largest employer, OHSU’s size contributes to its ability to provide many services and community support activities not found anywhere else in the state. OHSU serves patients from every corner of the state and is a conduit for learning for more than 4,300 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to each county in the state.

About SHOC
The Sherie Hildreth Ovarian Cancer (SHOC) Foundation is a multifaceted fundraising organization. In addition to raising funds for ovarian cancer research at Oregon Health & Science University, the SHOC Foundation works to raise awareness of ovarian cancer, educate women about the disease, and help empower women experiencing the disease. The SHOC foundation was established in 2005 by Sherie Hildreth and Cathy Ekerson in Gladstone, Ore.

###

Tanja Pejovic, M.D., Ph.D.
Oregon Health & Science University

RELATED STORIES:
Study Finds Aspirin, Vitamin E Don’t Prevent Cancer   Obesity may raise risk of ovarian cancer   Nanotech gene therapy kills ovarian cancer in mice   New platinum-phosphate compounds kill ovarian cancer cells   Ovulation induction linked with cancer risk   Ovarian cancer survival influenced by MD specialty   Roche upbeat on Avastin in ovarian cancer   Low dose naltrexone (LDN): Harnessing the body’s own chemistry to treat human ovarian cancer   Nanoparticle-Delivered “Suicide” Genes Slowed Ovarian Tumor Growth   Family breast cancer history ups ovarian cancer risk   More study needed on vitamin D-ovarian cancer link   New technique could sustain cancer patients’ fertility   DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients   Survivors of Rare Ovarian Cancer Retain Fertility, Have Positive Relationships   Possible way to treat ovarian cancer reported   Ovarian cancer drug trial reveals promising new treatment   Younger women survive ovarian cancer better   Platypus Link to Ovarian Cancer   St. John’s wort and polymeric nanoparticles to treat ovarian tumors using light   Ovarian Cancer Treatment Found to Significantly Improve Survival   Plant-based flavonoid may cut ovarian cancer risk   Researchers identify genes that may help in ovarian cancer diagnosis and prognosis

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]